Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 15Myeloid 4Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 166Rituximab 153Specimen Handling 111Biopsy 89Magnetic Resonance Spectroscopy 87Vincristine 85Doxorubicin 79Prednisone 78fludarabine 68venetoclax 65obinutuzumab 60ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 39blinatumomab 38Bendamustine Hydrochloride 34fludarabine phosphate 33prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 27Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gilteritinib × Lymphoid × 90 days × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡